Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Blood Cancer Journal, Published online: 16 September 2020; doi:10.1038/s41408-020-00358-3Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Source: Blood Cancer Journal - September 15, 2020 Category: Hematology Authors: Massimo Gentile Enrica Antonia Martino Andrea Visentin Marta Coscia Gianluigi Reda Paolo Sportoletti Francesca Romana Mauro Luca Laurenti Marzia Varettoni Roberta Murru Annalisa Chiarenza Ernesto Vigna Francesco Mendicino Eugenio Lucia Sabrina Bossio Anna Source Type: research